Regeneron, Sanofi Report Positive Topline Phase 2 Asthma Results
June 21 2019 - 6:39AM
Dow Jones News
By Colin Kellaher
Regeneron Pharmaceuticals Inc. (REGN) and Sanofi SA (SNY.FR,
SNY) on Friday said a Phase 2 proof-of-concept study of the
investigational antibody REGN3500 in asthma met its primary and a
key secondary endpoint.
The companies said REGN3500 as a monotherapy significantly
reduced loss of asthma control and improved lung function compared
with placebo.
REGN3500 inhibits interleukin-33, a protein that is believed to
play a key role in type 1 and type 2 inflammation, the companies
said. The antibody was invented using Regeneron's VelocImmune
technology and is being developed jointly by Regeneron and Sanofi
as part of a long-running collaboration.
Regeneron, based in Tarrytown, N.Y., and France's Sanofi are
studying REGN3500 in Phase 2 trials for asthma, chronic obstructive
pulmonary disease and atopic dermatitis--diseases where
inflammation is thought to play an underlying role.
The companies jointly market Dupixent, an antibody that inhibits
two other proteins and is approved in indications for asthma and
atopic dermatitis, or eczema.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 21, 2019 06:24 ET (10:24 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Sep 2023 to Sep 2024